Aashiish Agnihotri is Founder & CEO of xDot Medical, where he leads the company’s strategy, product development, and clinical efforts. He brings more than 20 years of experience across medical device product development and marketing leadership. Prior to founding xDot Medical, Aashiish spent more than a decade at Medtronic, where he held a series of progressively senior marketing leadership roles, including Director of Marketing, Senior Marketing Manager, Marketing Manager, and Senior Product Manager. During his tenure, he led commercialization strategies, product launches, and growth initiatives across multiple businesses. Earlier in his career, Aashiish held engineering roles at Smith & Nephew and Medtronic Sofamor Danek, where he focused on product development and innovation. With experience spanning engineering, product development, marketing, and executive leadership, Aashiish brings a unique perspective on the challenges of building and scaling MedTech companies, navigating clinical development, and bringing new technologies to market.

Charlie Attlan is Boston Scientific's Senior Vice President, Strategy and Business Development. In this role, he has oversight for corporate strategy, business development activity, mergers, acquisitions, divestitures, joint ventures licensing and distribution agreements, venture capital and minority investments. Prior to joining Boston Scientific, Charlie served as senior vice president, Credit Suisse (and its predecessor firm, Donaldson Lufkin & Jenrette), and in other roles of increasing responsibility, from 1999 until 2009, and an associate, and in other roles of increasing responsibility, at BT Alex Brown from 1993 until 1999. Charlie graduated magna cum laude, with a B.A. in Economics and Math, from Princeton University.   

Amanda Baumann is a senior engineering and healthcare technology leader with extensive experience in medical devices and orthopedic robotics. She began her engineering career at Johnson & Johnson, where she worked on neurovascular stroke treatment devices, building a strong foundation in customer-focused innovation. In 2008, she joined MAKO Surgical Corp., which became part of Stryker in 2013, designing orthopedic implants, and applications for the Mako Robotic Arm. With Stryker she advanced into leadership roles supporting all aspects of the Mako SmartRobotics research and development. Today, she serves as Senior Director, Ortho Clinical Solutions, leading clinical and application software efforts in hip, knee, and shoulder robotics.

Maria Berkman, MD, MBA, is a partner at Vensana Capital. Prior to Vensana, Maria was the Head of MedTech at Broadview Ventures and Managing Director of Longview Ventures—affiliate funds dedicated to cardiovascular disease and stroke. Maria currently serves on the boards of Alleviant Medical and Vensana Innovation, and previously served as Chair of AtaCor Medical (partnered with Abbott), and on the boards of Vectorious (acquired), Apama (acquired), CardiAQ (acquired), Remedy Therapeutics (acquired), Capricor (IPO), and Lyra Therapeutics (IPO). Prior to her venture career, Maria was a management consultant with Monitor Group and trained at Mass General Brigham’s Newton Wellesley Hospital. Outside her venture career, Maria serves on the Board of the Boston Museum of Science and as a member of the Acquisitions Circle at the Institute of Contemporary Art / Boston.

Adam is CEO of Alleviant Medical, Inc., a clinical-stage company developing minimally invasive therapies for heart failure patients. Previously, he was CEO and Co-Founder of TVA Medical, Inc. (acquired by BD), where they developed endovascular technology for patients in kidney failure. Prior, he held various commercial and R&D roles at Coalescent Surgical (acquired by Medtronic), MedicalCV, and Computer Motion (acquired by Intuitive Surgical). Adam also serves as a board member or advisor at select medtech companies. He received his BSE magna cum laude in biomedical engineering from Rensselaer Polytechnic Institute and his MSE in bioengineering from the University of Washington.

Mike Blue joined HistoSonics as President, CEO and Board Director in January 2017 and has over 25 years of leadership experience within the medical device sector. Since joining HistoSonics, the company has raised over $600M in equity financings, successfully completed pivotal trials in multiple clinical indications, and is now commercializing the company’s breakthrough Edison Histotripsy Platform around the world. In August 2025, Mike also assumed the role of Chairman of the Board upon the closing of a company-led majority ownership acquisition, valuing the company at over $2.25B. Prior to joining HistoSonics, Mike led the commercial organizations at NeuWave Medical, acquired by Johnson & Johnson in 2016, and superDimension, Inc., acquired by Covidien (MDT) in 2012. He started his career as an analyst at Anderson Consulting (Accenture).

As CEO of Resonant Link Medical, I am leading the effort to make wireless power and data transfer the foundation for intelligent, connected implants. Our Aurion WPT platform enables Intelligent Focal Technology (IFT), a new generation of smaller, smarter, and site-specific medical devices that deliver targeted therapy and diagnostics with greater effectiveness and less invasiveness. My experience spans the full MedTech value chain, from product strategy and commercialization to fundraising, team building, and corporate development. I am deeply motivated by the potential of technology to improve outcomes for undertreated patient populations and redefine how medicine is delivered.

Terry Bromley is CEO of Imbed Biosciences, driving commercial strategy, global growth, and innovation in the skin regeneration space. He brings more than 30 years of leadership experience across medical device companies—from early-stage ventures to large organizations, including Avita Medical, Crawford Healthcare, Emergent BioSolutions, and Bristol-Myers Squibb/ConvaTec. He has shaped go-to-market strategies, scaled commercial teams, and expanded operations across the U.S. and internationally. He also has a strong foundation in strategic marketing, having completed executive education at The Wharton School and Columbia Business School. He is passionate about building integrated, cross-functional strategies that advance market access, pipeline development, and long-term growth.

Scott Brown, PhD, is Chief Scientific Strategist at Bright Research, where he leads clinical strategy, trial design, statistical analysis, FDA interactions, and scientific communications for medical device companies. With more than 20 years of experience in clinical research, biostatistics, and product development strategy, Scott brings a unique combination of scientific expertise and practical MedTech experience. Prior to his current role, Scott served as a statistician at Bright Research and founded Altair Biostatistics LLC, where he provided clinical and biostatistical consulting to the medical device industry. He has also held senior roles at North American Science Associates and Covidien, where he led clinical trial design, statistical analysis, product development strategy, and FDA-facing activities across a range of therapeutic areas. Throughout his career, Scott has worked with startups, mid-sized companies, and large MedTech organizations to design and execute clinical trials, interpret results, and navigate complex regulatory pathways. He has supported more than 20 trials submitted to the FDA, appeared before FDA advisory panels, and contributed to multiple scientific publications. Scott is also Statistical Editor for Stroke: Vascular and Interventional Neurology, where he supports scientific manuscript review and statistical rigor in published research.

As Senior Partner at Intuitive Ventures Terri leads the firm’s investment strategy & platform by guiding investments that transform care. She works to scale impact across global medtech and digital health markets, collaborating with portfolio companies to support innovations that address significant unmet clinical needs and next horizon challenges in healthcare. Terri leverages deep investment and operating experience to foster the firm’s brand and refine its strategy. Terri has cultivated 30 years of strategic expertise working across corporations, start-ups and investment firms. Terri previously led the medtech investment strategy for Epidarex Capital’s Fund III US/UK and served as CEO and co-founder of Protaryx Medical. She spent a decade on the Senior Leadership Team at Edwards Lifesciences in several roles including overseeing global marketing and product strategy and business development. Earlier in her career, she held roles with increasing responsibility at Guidant Corporation and Covance Health Economics & Outcomes Services. Terri is a Trustee for the Roessler-Chadwick Foundation and an early member of MedtechWOMEN. Terri is a Board Observer for XII Medical, Flywheel, Medcrypt and Vahaticor. She previously served as a Board Director for Ryme Medical, Radiant Oximetry, Protaryx Medical, and Flashback Technologies. She holds a BS in Biology from Duke University and an MBA from the University of Southern California.

Justin Castelli is Vice President, Business Development of Boston Scientific’s Cardiovascular Segment. In this role, he oversees business development activity, mergers, acquisitions, divestitures, joint ventures licensing and distribution agreements, venture capital and minority investments for the following Boston Scientific business units: Interventional Cardiology, Vascular Therapies, Cardiac Rhythm Management/Diagnostics, Electrophysiology, and Interventional Oncology & Embolization. Justin joined Boston Scientific in 2010, and prior to business development held a variety of corporate finance roles across Global Business Services, Corporate FP&A and Investor Relations. Prior to Boston Scientific, Justin held finance and accounting positions at Teradyne and Textron Defense Systems. Justin received a B.A. in Finance as well as an MBA from Bentley University.

Successful, profit driven healthcare executive with over 20 years progressive experience in management, sales, clinical, and business development. Visionary leader and team player with stellar track record of superior performance in sales productivity, team building, customer relationship building, and account development. Notable interpersonal skills with a capacity to reach all levels of field personnel, management, and physicians. Multi dimensional, innovative strategist focused on consistent achievement of objectives. Recognized for an outstanding work ethic, integrity, and commitment to corporate goals and directives. Eternal optimist with a focused "can-do" attitude.

Kathryn Dehn, a partner at Fox Rothschild, focuses her legal practice on supporting her clients in the medical technology industry. She advises startups and emerging companies throughout their corporate lifecycles – from company formation and capital raising to their eventual exit. She regularly works with founders, management teams and boards in the role of outside general counsel, advising on strategic matters and negotiations. Kathryn has extensive experience representing medical technology companies with entity selection and initial formation, capital raising, technology licensing, clinical trial agreement negotiation, HIPAA compliance, data privacy and M&A transactions. In addition to her work with startup companies, Kathryn represents venture capital funds with respect to their portfolio investments.

Mark DuVal, J.D., FRAPS, is CEO of DuVal & Associates, P.A. Mark’s practice includes providing strategic regulatory advice, developing compliance programs, designing and implementing sophisticated marketing programs, counseling on reimbursement matters, conducting sales training and interfacing extensively on behalf of companies with the FDA with relation to product approvals and clearances, clinical trial negotiations, approvals, policy arguments, appeals, etc. Prior to founding the firm, Mark was general counsel for 3M Pharmaceuticals and Drug Delivery Systems working both domestically and internationally on assignment for 3M Health Care Systems, Ltd. in Europe. He then worked at Medtronic in Corporate Compliance for FDA, Anti-Kickback, False Claims Act, HIPAA & HITECH, and other advice related to the FDA-regulated industry.

Phil Ebeling is President & CEO of EmStop and a seasoned MedTech executive with broad leadership experience spanning product innovation, strategy development, commercialization, and global business growth. Trained as an engineer, Phil has led large, cross-functional organizations across the medical device and pharmaceutical industries, with a particular focus on delivering innovative healthcare solutions. Throughout his career, Phil has been recognized for leading business turnarounds, driving organizational transformation, and aligning teams around a common vision and strategy. His expertise includes product innovation, physician engagement, global commercialization, regulatory affairs, customer insights, and change management. Phil is known for his consultative leadership style and his ability to bring together physicians, researchers, and industry experts to shape next-generation technologies and strategies. He is passionate about coaching teams, developing talent, and helping organizations navigate complex clinical and business decisions. His leadership accomplishments include helping earn the Industry Week Best Plants Award, the Shingo Business Award, and recognition as a Lean Product Development Center of Excellence leader.

Chris Eso is Vice President of Coronary and Structural Hearth (CSH) Strategy, Growth and Business Development for Medtronic. Previously, Chris held the title for Vice President of Corporate Development, specifically covering the Cardiac and Vascular Group business units, including Cardiac Rhythm and Heart Failure (CRHF), Coronary and Structure Heart (CSH), and Aortic, Peripheral Vascular and endoVenous (APV). Chris joined Medtronic in August of 2011 and has held numerous positions of increasing responsibility and scope over his tenure at Medtronic. Chris has more than 18 years of successful professional experience, of increasing responsibilities, with the majority of his experience in a business/corporate development and strategy capacity within the pharmaceutical and medical device industries, in addition to Medtronic, including Allergan, Watson, Agilent Technologies and Peregrine Pharmaceuticals. Chris holds an MBA from Concordia University and BA in Public Relations, Communications from California State University, Fullerton.

Dr. Steven Farmer is a board-certified cardiologist and is a Senior Partner of ABIG Health. He previously served as Chief Strategy Officer for Coverage at the Centers for Medicare & Medicaid Services (CMS). In that role, he led an effort to streamline and accelerate the development of evidence-based coverage policies. He was the principal architect of the Transitional Coverage for Emerging Technologies (TCET) pathway and led the initiative to incorporate real-world evidence into coverage decision-making. Before his role as CSO, he was a Senior Advisor in the Center for Medicare and Medicaid Innovation, where he assisted with developing and refining value-based payment programs, with a particular emphasis on the Bundled Payments for Care Improvement Advanced model.

Bryan Feldhaus, J.D., LL.M., is President of DuVal & Associates, P.A. Bryan specializes in advising medical device, pharmaceutical and nutritional supplement companies on FDA law, regulations and guidance. His practice includes providing strategic advice and advocacy regarding regulatory submissions, designing and implementing sophisticated marketing programs, and interfacing extensively on behalf of companies with the FDA on promotional, inspectional and other enforcement matters. With his LL.M. in corporate compliance and organizational ethics, Bryan also counsels companies on compliance matters, conducts compliance assessments, and provides compliance training to ensure clients understand and achieve compliance goals in the context of their business objectives. Prior to joining DuVal & Associates, Bryan enjoyed a fourteen-year career as a trial attorney and shareholder at a Minneapolis law firm.

Jan founded Arboretum on the premise that innovation is key to delivering value in healthcare, a principle she developed working in the medical device industry for over two decades. Her investments focus on promising medical technologies that enable meaningful healthcare system savings while maintaining great clinical outcomes. Jan has led and held board roles in more than 25 investments across six funds including notable exits with HandyLab (acquired by BD), Esperion (Nasdaq: ESPR), NxThera (acquired by Boston Scientific), CardioMEMS (acquired by St. Jude Medical), and NeuMoDx (acquired by QIAGEN). Jan served on the National Venture Capital Association’s Board of Directors from 2015-2020 and in her last year, was the Board Chair. As chair, she prioritized industry-wide diversity initiatives and was instrumental in driving small business access to CARES Act financial assistance programs early in the COVID pandemic. In 2020 she testified at the US Senate on “Expanding American Entrepreneurship Outside Traditional Hubs”. Jan was recently awarded the Venture Vanguard Award by the NVCA (2023). Previous awards include: USA Top Women Dealmakers Award (2021), MichBusiness Women Leaders Hall of Fame (2020), Crain’s 100 Most Influential Women (2021, 2016), and as Crain’s Newsmaker of the Year (2015). She earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

Virginia is Vice President of Exploration at Edwards Lifesciences, where she builds external partnerships globally to advance breakthrough innovation. She has a track record of delivering innovation to patients, with roles spanning medical device, pharmaceutical and nutrition businesses. Virginia has focused on advancing innovation, with R&D, Program Management, and Business Development leadership roles at Stryker, Abbott, and Johnson & Johnson. She chairs the Cornell Biomedical Engineering Advisory Council, is an AIMBE Fellow, and is a co-founder of MedtechWomen. She holds B.S. and M.Eng. degrees in Mechanical Engineering from Cornell and a Ph.D. in Mechanical Engineering from Stanford.

Jake Goble, PhD, MBA, is Head of Business Development at Gore Medical, where he leads the organization's M&A, partnerships, and investment strategy to expand the company’s impact as an endovascular innovator. Since joining Gore in 2007, Jake has held leadership roles across cardiac, structural heart, aortic, surgical solutions, and innovation businesses, shaping portfolio strategy, advancing new technologies, and guiding teams through transformation and growth. He holds a PhD and MS in Bioengineering from Arizona State University and an MBA in International Business. Jake is a co-author on multiple peer-reviewed publications, an inventor on medical device patents, and a frequent speaker at industry congresses. He lives in Flagstaff, Arizona with his family.

Nir joined Business Development in 2022. He is a member of the Mayo Clinic Business Development Executive Committee and leads the Technology Development Unit, responsible for facilitating the development and commercialization of Mayo Clinic technologies by collaborating with Mayo Clinic staff, industry collaborators, entrepreneurs, and investors. Prior to joining Mayo, Nir was CEO of Trendlines Innovation Labs (TIL), which focuses on in-house and collaborative invention and investment opportunities in the life science space. Prior to his appointment as CEO, he served as TIL’s VP Business Development. Before Trendlines, he was Director of Commercial Development for Europe at INSIGHTEC Ltd., a global MR-guided focused-ultrasound surgery company. Nir holds a BSc in engineering from La Sapienza University of Rome.

Senior Conference Director at Cambridge Innovation Institute.

Robert J. Greenberg MD, PhD, joined huMannity (formerly Alfred Mann Foundation) in 1998, was elected Chairman of the Board of Directors in 2004, and became its Chairman and CEO in 2021. He was a co-founder and former CEO and Chairman of the Board of Second Sight Medical Products, Inc. (formerly NASDAQ: EYES) in Los Angeles, California. Dr. Greenberg is a leader in the field of neural prosthetics—having developed and brought to market the world’s most advanced implantable neural stimulator at the time, the Argus II visual prostheses, to treat retinitis pigmentosa, a form of blindness. At Second Sight, he also oversaw the successful development and human implantation of a wireless cortical visual prosthesis, the Orion, which has the potential to treat nearly all forms of blindness and other brain diseases. Dr. Greenberg was also an Independent Director at Pulse Biosciences (NASDAQ: PLSE), a company developing therapies based on nanosecond pulsed electric field technologies for oncology and dermatology applications. He was previously a medical reviewer at the FDA’s Office of Device Evaluation. Since 2001, he has also been the Chairman of the Board of Directors at the Southern California Biomedical Council, a nonprofit trade association supporting the healthcare industry in the Greater Los Angeles region. Dr. Greenberg is the recipient of numerous honors and awards, has over 260 issued US patents and over 100 international patents, and has published over 60 articles. He received MD and PhD degrees from The Johns Hopkins School of Medicine in Baltimore, Maryland. He has been a member of the New York Academy of Sciences, a fellow of the American Institute for Medical and Biological Engineering, a fellow of the National Academy of Inventors, and a fellow of the IEEE.

• John Haagen is CEO and Co-Founder of VISUM, a strategic MedTech film firm producing cinematic films that support product launches, clinician adoption, investor confidence, and commercialization.

• VISUM helps MedTech innovators close the Narrative Gap between complex clinical innovation and market understanding by translating technical, clinical, and commercial value into compelling visual stories built around authentic voices, real environments, and cinematic execution.

• John holds a B.S. in Electrical Engineering and Computer Science from the University of Michigan College of Engineering.

• Disclosure: John also serves as Principal of Haagen Ventures, actively investing in and advising select MedTech and industrial technology companies on commercial growth strategy.

Mr Haines has 25 years’ experience in leading global businesses in pharmaceuticals, biotechnology, and medical devices. As the current CEO of EchoIQ, Mr. Haines focuses on the intersection of innovative technology utilizing AI and the impact of cardiovascular disease around the world. Prior to EchoIQ, Mr. Haines was head of Asia, Middle East, Turkey, and Russia for a major biotechnology company where he managed over $1.2B in revenue. Prior to that Mr. Haines was the commercial leader for a publicly traded medical device company in the United States, where he built go to market strategy and launched several new novel devices into the US market. As a leader, Mr. Haines has launched innovative technologies globally with extensive experience in regulatory approvals, reimbursement, commercialization, and scaling businesses. Mr. Haines has a rich history of building high performing teams with a focus on aligning purpose with clear strategy. Inspired by nearly 20 years of working in biotechnology and seeing firsthand the power of patient engagement and partnership, Mr. Haines has been focused on working closely with patient organizations, community-based groups, physicians, and government health systems to bridge the gap of healthcare access and treatment. Mr. Haines is currently residing in Arizona where he manages the day-to-day activities for EchoIQ covering both the US and Australian teams.

Brett Hanson, a partner at Fox Rothschild, represents public and private companies — from emerging businesses to Fortune 500 corporations — in a broad range of transactions, including mergers and acquisitions, public and private securities offerings, joint ventures and strategic investments. He regularly assists early stage companies, particularly medical device and other technology companies, with formation, equity capital raising, technology acquisition and licensing, as well as mergers and acquisitions and related matters.

Eric brings more than two decades of leadership across early-stage ventures and multinational healthcare companies to AIQ and its mission to improve care for patients with late-stage cancer.

Since joining AIQ as President and CEO in 2018, he has guided the company through multiple rounds of equity financing, team construction, product commercialization, and international expansion.

His background includes serving as CEO of Swallow Solutions, a medical device startup, and leading GE Healthcare’s Premium Anesthesia and Respiratory Care franchise. He also held key marketing and business development roles at Baxter Healthcare across the U.S. and Latin America.

Eric holds a B.S. in Chemical Engineering from Rice University and both an MBA and a Master of Engineering Management from Northwestern University’s Kellogg School of Management.

Kate Jackson Hobbs, CFA is VP of Corporate Development Strategy at Intuitive, where she runs the Corporate Development function and partners with the CEO and senior leadership on growth strategy and buy/build/partner decisions across emerging technology categories. She brings more than two decades of healthcare investing experience from T. Rowe Price, Wellington Management, Citadel, and other leading institutions, having advised on more than $30 billion in healthcare investments with deep focus in medtech. She has served as Board Observer to Kardium and Galvanize Therapeutics and holds an MBA from Stanford GSB and a BA, cum laude, from Harvard College.

Frank Jaskulke works with smart people who save lives, and if he does his job well, they save more lives. With nearly two decades at Medical Alley Association, he served in various leadership roles, most recently as Vice President of Innovation and Head of Medical Alley Starts. Frank has been instrumental in advancing the medtech sector, connecting companies with partners, investors, and key talent. He has a proven track record in international business development and strategic services, particularly for startup companies. Frank holds a Master of Political Leadership from the University of Minnesota Duluth and a Bachelor of Arts in Political Science from the University of Minnesota. He is known for his dedication to fostering innovation and his deep connections within the medtech community.

Patrice Kloss, partner at Fox Rothschild and co-chair of the firm’s MedTech Practice, is a veteran medical technology counselor and transaction attorney. Patrice has represented early stage and middle market medical technology companies in financing, acquisition and sale transactions for more than 20 years. She assists medtech companies with formation, equity capital raising, technology acquisition and licensing, as well as mergers and acquisitions and related matters. Patrice also advises boards of directors on fiduciary duties in connection with financing and sale transactions.

Mark Leahey is the President & CEO for the Medical Device Manufacturers Association (MDMA), the leading national trade association representing hundreds of innovative and entrepreneurial medical technology companies in Washington, DC. His responsibilities include advocating on behalf of the medical device industry to Congress, the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and other federal and state agencies.

David has 25 years of healthcare experience evaluating Medical Device, Life Science Tool, Diagnostic and Digital Health companies and advising boards on strategic and financial direction. Prior to founding Gilmartin Capital, David was a Managing Director at Morgan Stanley and Head of Morgan Stanley’s medical technology equity research practice for the last 15-years. He was a top ranked analyst at Morgan Stanley and in the Institutional Investor (II) Medical Supplies & Devices annual poll. Before joining Morgan Stanley, David was a partner and top ranked medical technology analyst at Thomas Weisel Partners and a founding member of the healthcare practice. David received a BA in healthcare policy with honors from the University of Pennsylvania. David serves as an advisor to Equalize Health, a non-profit that is developing medical devices for underserved populations. He lives outside of San Francisco with his wife Lynn, daughter Olivia, son Jack, and dog Tucker. David is a struggling guitar player, recovering a cappella singer, and he loves the mountains in any season.

Chris focuses his consulting practice on the intersection of clinical evidence, regulatory requirements, and payer coverage policies to ensure research programs can support product approval requirements and demonstrate value to payers and providers. A biostatistician by training, he has over 25 years of experience in the medical device industry and has successfully negotiated numerous study designs with FDA and several OUS regulatory agencies.

Geoff Martha is Chairman and CEO of Medtronic, a global leader in healthcare technology. Under his leadership, 95,000 Medtronic employees deliver transformative medical innovations to alleviate pain, restore health and extend life for 79 million patients annually. A driven and innovative executive, Geoff was named CEO in April 2020 after joining Medtronic in 2011 and holding various enterprise-level leadership roles in strategy, corporate development, and business oversight. He previously spent nearly two decades in senior leadership roles at GE Healthcare and GE Capital and has been recognized multiple times by Modern Healthcare as one of the 100 Most Influential People in Healthcare. Geoff is passionate about the intersection of healthcare and technology. He actively participates in global business organizations, including the Business Roundtable, the World Economic Forum’s International Business Council, and the U.S.-China Business Council. He also serves as Treasurer of AdvaMed and Chairman of the Minnesota Business Partnership. He is on the board of NextEra Energy, a Trustee for the Asia Society, and on several non-profit boards including the Medtronic Foundation, the Northside Achievement Zone (NAZ), and YMCA of the North. Geoff holds a finance degree from Penn State University.x`

Scott McCarty is a senior member of SVB’s National Life Science and Healthcare Team for 21+ years supporting healthcare innovation with a full suite of senior commercial banking services tailored specifically for high growth entrepreneurial life science and healthcare businesses of all stages. Scott is currently leading national business development and is spending much of his time deploying senior debt growth capital ($1-200MM) to Series A+ private and public companies across all healthcare innovation sectors.

Chas McKhann is a seasoned executive and board member in the medical technology industry, having held CEO or Chief Commercial Officer roles in four companies that have been acquired for ~$3.4 billion. Chas currently serves as Executive Chair at Distalmotion, a surgical robotics company, and as an independent board member at Envoy Medical, a cochlear implant company and Exagen, a medical diagnostics company. Chas is also a Sr. Advisor to McKinsey and Company. Recently, Chas served as President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific. Previously, Mr. McKhann served as Chief Commercial Officer at Torax Medical and Intersect ENT. Chas holds a B.A. in Political Science and an M.B.A. from Stanford University.

James K. Min, MD is a former Professor of Radiology and Medicine at Weill Cornell Medical College and the Director of the Dalio Institute of Cardiovascular Imaging (ICI) at NewYork-Presbyterian. He is a board-certified cardiologist with a clinical focus on cardiovascular disease prevention and cardiovascular imaging. With a clinical and research focus on coronary artery disease, Min has published more than 500 peer-reviewed manuscripts that have been funded, in part, by numerous grants awarded by the National Institutes of Health and the Dalio Foundation. Min has served as Principal Investigator on numerous landmark multicenter clinical trials and registries, including the ACCURACY, CONFIRM, CONSERVE, CREDENCE, ICONIC and PARADIGM trials. Min is also the director of a state-of-the-art core laboratory for coronary computed tomography for several multicenter clinical trials, including for the PACIFIC and ISCHEMIA trials. Min is Past President of the Society of Cardiovascular Computed Tomography (SCCT), where he served as Chair for the Annual Scientific Sessions meeting for 5 years. He was the 2017 recipient of the SCCT Gold Medal Award for lifetime achievement in the field of CT. He is a leader in the American College of Cardiology where he has served on the Task Force for Clinical Expert Consensus Documents and the Task Force for Appropriate Use Criteria. Min served as Editor-in-Chief of the Journal of Cardiovascular Computed Tomography, Associate Editor for the Journal of the American College of Cardiology: Cardiovascular Imaging, Associate Editor of the Journal of Nuclear Cardiology, and on the Editorial Board of Circulation: Cardiovascular Imaging. Min has received numerous awards and distinctions, including recently being inducted into the American Society of Clinical Investigation and the Academy of Radiology Research. For Min, the development, validation and dissemination of Cleerly’s products and services offer him an opportunity to translate the large-scale clinical trial research he has spent doing in the last 17 years into daily clinical practice through innovative solutions in coronary heart disease that have not existed in the marketplace to date. Min received his BA from the University of Chicago, and his medical degree from Temple University Medical School. He completed his internship, residency and cardiovascular medicine fellowship at the University of Chicago Hospitals.

Ramin Mousavi is a dynamic and seasoned healthcare executive, currently serving as the President, CEO, and a member of the Board of Directors at CathWorks, a digital health company revolutionizing the diagnosis and treatment of cardiovascular disease through advanced computational science and artificial intelligence. He has an outstanding history of building high-performing organizations and achieving exceptional results in the medical device and high-tech industries—from early development to global commercialization of breakthrough and transformational innovations. Professional Background He is currently the President and Chief Executive Officer (CEO) of CathWorks, an innovative global medical device company dedicated to improving patient care. Mousavi's career spans various leadership roles across multiple industries. Prior to his tenure at CathWorks, he led the patient monitoring and digital health portfolio at Baxter International. He also held significant positions at Edwards Lifesciences, Panasonic Avionics, and Rockwell Collins, gaining extensive experience in general management, marketing, strategy, product development, and commercialization. Education Mousavi holds a dual Bachelor of Science degree in Computer and Electrical Engineering from the University of California, Irvine. He furthered his education with an MBA from the Paul Merage School of Business at UC Irvine. He completed a Healthcare Executive Leadership program for Business Innovation in Global Healthcare from Harvard Business School. Community Engagement & Recognitions An active alumnus, Mousavi has contributed to the UC Irvine community by serving as Chair of the Dean’s Leadership Circle at the Paul Merage School of Business. He has been instrumental in expanding the DLC Grant Initiative, supporting students, faculty, and the local business community. He is currently the Vice-Chair of the Dean’s Advisory Board.

Maggie Nixon joined Capstan Medical in 2022, after spending more than two decades at Intuitive Surgical, where she held a wide range of increasing leadership roles across R&D, clinical development, quality, and regulatory. Known for bringing teams together to solve complex problems, Maggie helped guide technologies from early concept through commercialization. Before joining Capstan, Maggie led Intuitive’s China operations and strategy, helping expand the company’s presence and capabilities in one of the world’s fastest-growing healthcare markets. At Capstan, Maggie is focused on building a company that moves quickly, tackles hard problems, and works closely with physicians & engineers to determine how heart-valve therapies can be re-imagined using robotics, cutting-edge implant and catheter technology, and AI-based imaging.

Chris Owens has over 30 years of medical device experience holding senior-level executive positions in both commercial and technical areas. He has held CEO and executive leadership roles, served as an independent board of director, held board/CEO advisor roles and has been an integral member of board compensation committees with various organizations. Chris has extensive experience in commercializing and scaling businesses, developing products from early stage to product launch, driving clinical strategy and trials including HEMA strategies, in compensation related matters and in raising capital to sustain company growth through value creating strategies. He has spent extended time in various markets throughout his career holding positions in product development (R&D), manufacturing, sales, marketing and clinical. From 2014-2023, Chris was the President & CEO of Gynesonics Inc., a privately held medical device company dedicated to advancing women’s health by developing transcervical, uterus-preserving, incision-free, minimally invasive technologies for diagnostic and therapeutic applications. Chris scaled Gynesonics delivering triple digit revenue growth, obtained regulatory clearances and positive HEMA results including obtaining coverage, coding (CAT I code) and payment - revamped company strategies delivering best-in-class clinical data-outcomes (including 15 trials and studies and over 40 publications), completed technology improvements while driving elite gross margins. Gynesonics was acquired by Hologic in late 2024, post the CAT I code going into effect and shortly after Mr. Owens departed the organization. In addition, Mr. Owens served on the board of RF Surgical, with products for the detection of retained surgical sponges, which was acquired by Medtronic in 2015. Prior to joining Gynesonics and RF Surgical, Chris was the President & CEO of IDEV Technologies from 2008-2013. IDEV was a privately held medical device company focused on the peripheral vascular market with the development of the Supera stent, which was acquired by Abbott in 2013. From 2005-2008, he served as Vice President of Worldwide Marketing for MicroVention, a startup medical device company in the neurovascular space that was purchased by Terumo Corporation in 2006. From 2003-2005, he was the Vice President of Global Research and Development for the Surgical Division of Bausch & Lomb. Chris earned a bachelor's degree and a master's degree in Plastics Engineering from the University of Massachusetts, Lowell, and an MBA from the University of Phoenix.

Michael J. Partsch has over 34 years of experience in venture investing and start-up company development in the life sciences industry. During those years he has developed a highly refined skill at forming and interacting with entrepreneurial management teams, particularly excelling in the area of university-based spinouts. Mike’s venture capital experience spans four firms: Accuitive Medical Ventures, Versant Ventures, EDF Ventures, and the CEO Venture Fund. Additionally, Mike was selected as a Kauffman Fellow, a two-year post-graduate fellowship in venture capital sponsored by the Kauffman Foundation. In 2018, Mike became the inaugural Chief Venture Officer at the Wisconsin Alumni Research Foundation (WARF). In this role, he manages a venture fund and portfolio exceeding $200 million while leading new initiatives focused on company creation. He currently serves on the boards of AIQ Solutions, Atrility Medical, Gregor Diagnostics, and Promiss Diagnostics. Previously, Mike founded AcceleMed Management, Inc., where he played multiple roles in the development of innovative medical device technologies. AcceleMed specialized in sourcing, founding, and managing early-stage medical device companies, with Nalu Medical (www.nalumed.com) being a notable example. Additionally, he served as an independent board member for MyoScience (Menlo Park). As a co-founder of Accuitive Medical Ventures (AMV), Mike was instrumental in devising the firm’s investment strategy, raising its first $55 million fund, and overseeing investments in 10 portfolio companies. At AMV, he focused on medical device investments, contributing significantly to companies like AcuFocus, MyoScience, and Neuronetics. He also played a key role in raising $105 million for AMV’s follow-on second fund, AMV II. Before AMV, Mike spent three years with Versant Ventures, a $650 million healthcare-focused venture fund. At Versant, he focused on medical devices, contributing to investments in IntraLase Corp. (NASDAQ: ILSE), Glaukos, Confirma, Cameron Health, AcuFocus, NeoVista, Inogen, and Second Sight. During his Kauffman Fellowship at EDF Ventures in Ann Arbor, Michigan, Mike served as interim CFO of IntraLase Corp. (NASDAQ: ILSE) and founded HandyLab, Inc., which was later acquired by Becton Dickinson for $275 million. Continuing his persistent habit of working while going to school, Mike reviewed deal flow and performed due diligence at the CEO Venture Fund in Pittsburgh, while completing his MBA. Following his MBA, Mike contributed to entrepreneurship education as a co-developer and instructor of the James R. Swartz Entrepreneurship Boot Camp—a two-week intensive program for MBA students at Carnegie Mellon University. This bootcamp ran for three consecutive years, proving the value of this education for incoming MBA students at Carnegie Mellon University and was eventually incorporated in the university’s pre-MBA general curriculum. Mike's entrepreneurial journey began at the University of Pennsylvania, where he co-founded Neose Technologies as an undergraduate. After graduation, he continued as a scientist, helping lay the foundation for Neose’s early biochemistry projects. Neose went public in 1996 (NASDAQ: NTEC). Mike holds a Bachelor's degree from the University of Pennsylvania, with a dual major in Biology and Philosophy of Science and a minor in Chemistry. He also earned an MBA from Carnegie Mellon University, with dual concentrations in Finance and Entrepreneurship.

Josh is a founder and managing partner of CHV and a member of the firm’s Investment Committee. He is actively involved in all aspects of fund management, including investments and capital raising, and has led investments in the medical device, women’s health, and molecular diagnostics markets for over 20 years. Josh led CHV’s investments in Allegro Diagnostics (acquired by Veracyte), Vortex Medical (acquired by AngioDynamics), SevenOaks Biosystems (acquired by Medline), Sera Prognostics (NASD: SERA), Saphena Medical (acquired), Conformal Medical (acquired by WL Gore), Brixton Biosciences, EyeCool Therapeutics, Epitel, and Esperto Medical. He has represented CHV on the boards of each of those companies. From 2000 to 2007, Josh was the Managing Partner of Catalyst Health and Technology Partners, LLC., an organization that made early-stage investments in healthcare and technology-focused companies. During that time, Josh led investments in Novazyme Pharmaceuticals (acquired by Genzyme (Sanofi)), BioTrove (acquired by Life Technologies (Thermo Fisher), and Biocius Life Sciences (acquired by Agilent Technologies). He served as the Chairman of BioTrove and a director of Biocius Life Sciences, and a board observer to Novazyme Pharmaceuticals. From 1997 to 2000, he was a manager at the Lucas Group, a boutique strategy-consulting firm, where he led engagements advising healthcare, life science, and technology-based companies. Prior to that, Josh co-founded, managed, and built a new business unit at Russelectric, a privately held engineering technology firm that is now part of Siemens. Josh previously held project and engineering management positions at Pratt & Whitney Aircraft, focused on the control system of the USAF F-22 fighter engine. Josh received an M.B.A. from the Harvard Business School and a B.E. in Electrical Engineering and Mathematics from Vanderbilt University.

Todd serves as the Chairman of the Board of Directors of AdvaMed ACCEL. Todd was most recently the President and CEO, of WellAir, a healthy indoor air solutions provider which recently acquired UV Innovators, where Todd served as executive chairman. Prior to joining WellAir, Todd was a Revival Resident Operating Partner. Before UV Innovators, Todd was the President and CEO of TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. Todd’s previous roles included Global President of Johnson & Johnson Cordis; where he led a multi-billion-dollar business unit comprised of 3 distinct companies; Cardiology, Neurovascular, and Peripheral Vascular. Todd has also held various executive positions, including Liquidia Technologies' CEO, a nanotechnology-based healthcare company, in Research Triangle Park, North Carolina. He served 14 years in various management roles at Johnson & Johnson's Ethicon Endo-Surgery Division and Boston Scientific, where he rose to Vice President, Global Sales, and Marketing, Neurovascular Division. In addition to serving as Chairman of the Board of Directors of AdvaMed ACCEL, Todd is on the board of directors of Revival portfolio companies Swan EndoSurgical and Distalmotion. Todd also serves on the board of directors at Humacyte, a regenerative medicine company leveraging a scalable technology platform to develop bioengineered human tissues. He serves on the Educational Foundation for the University of North Carolina at Chapel Hill, where he is the immediate past Executive Chairman of the Board. He was named to TIME Magazine’s 2018 list of 50 Most Influential People in Health Care.

Stacey Pugh is a seasoned medical technology executive with more than 20 years of experience spanning clinical research, product development, and global commercialization. Her career traces an uncommon arc—from critical care nursing to chief executive—giving her a rare combination of patient-centered insight and operational command across five medtech companies, seventy-plus products. She currently serves as Chief Executive Officer of Endogenex, a clinical-stage medical device company based in Minneapolis, Minnesota, that is developing a first-of-its-kind endoscopic therapy for type 2 diabetes and metabolic disease. Appointed CEO in March 2023, Stacey leads the company through its pivotal clinical program and the continued development of the Endogenex System—an outpatient, non-thermal pulsed electric field therapy designed to regenerate the duodenal mucosa and submucosa and restore healthy metabolic signaling in patients with T2D. Career Highlights Prior to Endogenex, Stacey was Chief Commercial Officer at Butterfly Network (Nasdaq: BFLY), the pioneer of handheld, whole-body ultrasound, where she led the planning, organization, and execution of global sales and marketing. Before Butterfly, Stacey spent more than a decade in neurovascular leadership at Covidien and Medtronic. She served as President of the Neurovascular Operating Unit at Medtronic, where she provided global strategic leadership and drove revenue growth toward the business’s $1 billion milestone Earlier in her career, Stacey held a progression of clinical development roles at Kinetic Concepts, Inc. (KCI), the wound-care and regenerative medicine leader, where she advanced from clinical research into senior clinical leadership. Board and Industry Service Stacey is currently Chair of the Board of BrainQ Technologies, an AI-driven precision therapeutics company whose BQ 2.0 device received CE Mark as a breakthrough therapy for stroke recovery in early 2025. She originally joined BrainQ’s board in August 2021 and was elevated to Board Chair in January 2025. She has also served as a director and executive committee member on the boards of two leading industry organizations: the California Life Sciences Association (CLSA), where she was appointed in 2019, and the Massachusetts Medical Device Industry Council (MassMEDIC), where she joined the board in 2022 and went on to serve as Vice Chair of the Executive Committee. Approach Stacey is known for pairing deep clinical empathy—rooted in her years at the bedside—with disciplined commercial execution. She has built and led global teams across research and development, clinical affairs, regulatory, medical affairs, sales, and marketing, with a consistent record of launching innovative therapies into complex disease categories. At Endogenex, she is focused on bringing a new category of regenerative therapy to the more than 30 million Americans living with type 2 diabetes whose needs remain unmet by current pharmacologic options.

Dr. Shri Raghunathan is the Founder and CEO of Noctrix Health, where he has led the company from inception to a 125+ person, multi-state organization pioneering a new standard of care for Restless Legs Syndrome (RLS). Under his leadership, Noctrix has achieved 25 consecutive quarters of strong performance, secured a new reimbursement code, navigated key FDA and CMS milestones, and launched its flagship TOMAC/Nidra therapy nationally. Shri is the primary author on regulatory submissions, a liaison to leading clinicians in sleep medicine, and inventor on more than 20 patents. A trained electrical engineer and circuit designer, Shri began his career developing telecommunications chipsets before completing a Ph.D. at Purdue University, where he created one of the the world’s first implanted responsive neurostimulation prostheses for epilepsy, work recognized by IEEE and TSMC. His industry experience spans Cyberonics (now LivaNova), Stanford Biodesign, Action Potential Venture Capital, and The Foundry, where he contributed to early R&D for FIRE1, now a leading heart-failure monitoring company. Shri has raised over $100M across equity, debt, and grant financing, combining deep technical expertise, clinical insight, and entrepreneurial vision. His bottom-up, hands-on leadership philosophy continues to shape Noctrix Health’s mission to revolutionize treatment for RLS and transform patient lives.

James is an experienced medical device executive with over three decades of expertise in strategic planning, commercial execution, fundraising, and M&A. He currently serves as the CEO and President of Conformal Medical, a device company focused on the development of the AcuFORM designed for left atrial appendage occlusion. Reinstein served as President, CEO, and board member at several other early-stage companies where he raised over $300M in capital funding and transacted multiple companies. Earlier in his career, Reinstein also served as Senior Vice President and Chief Commercial Officer for LivaNova and spent several years at Boston Scientific in multiple roles and geographies. Since 2015, he has served as a General Partner with Palo Alto Medtech Advisors. Reinstein holds a bachelor’s in business administration, marketing, from the University of Georgia and completed executive management training at INSEAD in Fontainebleau, France.

Jon Salveson is the vice chairman of Piper Sandler investment banking. Prior to his current position, he was the global head of investment banking for seven years. Before that, Salveson spent his career at Piper Sandler building a leading healthcare underwriting and M&A advisory practice. In 1996, he opened the Piper Sandler office in Menlo Park, California, where he was instrumental in establishing a large technology and healthcare presence in Silicon Valley, including over 100 investment banking and research professionals. Salveson graduated from St. Olaf College and received a master’s degree in management from the J.L. Kellogg Graduate School of Management at Northwestern University. He serves on the boards of Artivion (NYSE: AORT) and several private healthcare companies. Salveson is also a former member of the board of regents at St. Olaf College and the chairman of the endowment, as well as a former trustee of the Oakleaf Endowment Trust for the Minnesota Orchestra.

Alexander is a partner at Endeavour Vision, leading investments in healthcare technologies across multiple therapeutic areas. He brings over two decades of business and strategy experience in medical device and high-growth companies. He currently represents Endeavour Vision on the boards of FLEX Vascular and HealthJoy. He previously served on the boards of Relievant MedSystems (acquired by Boston Scientific), Gynesonics (acquired by Hologic), V-Wave (acquired by Johnson & Johnson), VertiFlex (acquired by Boston Scientific), and Rapid Micro Biosystems (NASDAQ: RPID), and co-led the firm’s investment in Kestra Medical Technologies (NASDAQ: KMTS). Prior to joining the Endeavour Vision team, Alexander spent nine years with Biosensors International Group, an interventional cardiology company, where he served as vice president of business development. He previously worked with LogiSpring Ventures, MicroStrategy, and McKinsey & Co. Alexander holds an MBA from INSEAD and a BSFS in economics from Georgetown University.

Zack Scott, MD General Partner, Norwest Dr. Zack Scott previously served on the board of directors for Cianna Medical, Coherex Medical, Evidation Health, Providence Medical Technology, Respicardia, Spiration, and Syapse.

Prior to joining Norwest, Zack was the co-founder and managing partner of Revelation Partners, a dedicated secondary investor specializing in shareholder liquidity and growth capital for healthcare companies. During his time at Revelation Partners, he made notable investments in Omada Health, iRhythm Technologies (IPO), SetPoint Medical, and Respicardia (acquired by Zoll Medical). Before working in private equity, Zack was a General Surgery resident at Oregon Health & Science University in Portland, Oregon. He earned his M.D. from the University of Texas Health Science Center at San Antonio where he was a member of the AOA Medical Honors Society, and subsequently earned an M.B.A. with a specialized certificate in Health Sector Management from The Fuqua School of Business at Duke University where he was a Fuqua Scholar.

Jeff Shuren is a Founding Partner of White Oak 66 Capital and an advisor to capital investment firms and medical device incubators. He previously served as the Director of the Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH), a role he held for 15 years. During his tenure, Jeff conceived and implemented initiatives to modernize the regulation of medical devices through a holistic, patient-centric, customer service-focused, total product life cycle approach to oversight and the organizational structure of CDRH. He previously held several policy and planning positions in the FDA’s Office of the Commissioner and the Centers for Medicare and Medicaid Services’ Coverage and Analysis Group, supervised and designed clinical studies on human reasoning as a Staff Volunteer in the National Institutes of Health’s National Institute of Neurological Disorders and Stroke Cognitive Neuroscience Section, and served as a detailee on the Senate HELP Committee. Jeff is a neurologist with subspecialty training in behavioral neurology and neuropsychology, and served as an Assistant Professor of Neurology at the University of Cincinnati. He received his MD from Northwestern University School of Medicine and his JD from the University of Michigan Law School.

Amrinder Singh is a Partner at Vensana Capital and joined the firm in 2021. Amrinder has nearly two decades of medtech operating and investing experience, ranging from engineering, corporate strategy, and venture capital investing. Prior to Vensana Capital, Amrinder was a Senior Investment Director at Medtronic Ventures where he supported new investments in the medtech and digital health spaces, providing operational and board management support to portfolio companies. Prior to his investment career, Amrinder led Business Development & Strategy for Medtronic’s care management services, helping to shape the vision for Medtronic's value-based healthcare strategy. Amrinder started his career at Medtronic within the Corporate Strategy group. Before joining Medtronic, Amrinder held product management and engineering positions at Thoratec Corporation. Amrinder graduated from University of California, Davis in Biosystems Engineering and earned his MBA from Northwestern University, Kellogg School of Management.

Marit Slawson is President of Bright Research, where she leads the company’s operations, growth strategy, and client delivery across a broad portfolio of medical device clinical research programs. She has been with Bright Research for more than seven years, previously serving as Director of Project Planning and Analysis and Program Manager, where she helped scale the organization through improvements in systems, processes, quality, and business operations. Marit brings extensive experience in clinical operations, project management, quality systems, and new product development. Prior to joining Bright, she held engineering and program management roles at Abbott and St. Jude Medical, where she led cross-functional teams through product development, clinical studies, and commercial launch activities for cardiovascular and electrophysiology technologies. Her experience spans program planning, risk management, resource allocation, quality systems, regulatory support, and commercialization across global markets. Known for combining operational rigor with flexibility, Marit is passionate about helping MedTech companies navigate complex clinical development pathways while building strong partnerships with sponsors and internal teams. She is particularly focused on creating coordinated, efficient study experiences that anticipate challenges, support growth, and help bring new medical technologies to market.

Mostafa leads product management for NVIDIA Healthcare Robotics, overseeing the NVIDIA Holoscan and Isaac for Healthcare platforms. His passion is to enable medtech companies to deliver intelligent, patient-centric solutions and disrupt the way diseases are prevented, diagnosed, and treated. Before NVIDIA, Mostafa worked in the medtech industry in various capacities from strategy manager to scientist, bringing products (software and hardware) from concept to launch. Mostafa holds a Ph.D. in mechanical engineering and an MBA from the University of Minnesota.

Annie Wernig is a Managing Director in J.P. Morgan’s Healthcare Investment Banking group. Annie joined the J.P. Morgan Healthcare Investment Banking team in 2013 and is focused on the medical technology sector. She graduated from Princeton University with a B.A. in Economics and has an MBA from the University of Virginia’s Darden School of Business.

Darshana is a Founder and Managing Partner of CHV and a member of the firm’s Investment Committee. She is actively involved in all aspects of the fund, including investments and capital raising, and has led investments in the medical device, women’s health and diagnostics markets for over 15 years. Darshana led CHV’s investments in Augmenix (acquired by Boston Scientific), nVision Medical (acquired by Boston Scientific), Maxwell Health (acquired by SunLife), Aria CV, PanTher Therapeutics, AtaCor Medical, Instylla, Avive, Rejoni and Venova Medical. She has represented CHV on the Boards of each of those companies. Prior to joining CHV in 2007, Darshana was an Investigator at Vertex Pharmaceuticals, and an integral part of drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company and at the Dana Farber Cancer Institute. Darshana currently serves as an advisor of the Deshpande Center for Technological Innovation at MIT, (a foundation that helps MIT students and faculty commercialize breakthrough technologies and inventions), as a Board Director of The New England Venture Capital Association (NEVCA) and as a lead advisor to the Portfolia FemTech fund (an investment fund designed for women). Darshana received an M.P.A. from Harvard University, an M.A. in Cell and Molecular Biology from Boston University, and a B.S. in Biochemistry from Bombay University in Bombay, India.